Complementation of Monoclonal Antibodies DF3 and B72. 3 in Reactivity to Breast Cancer
Monoclonal antibodies (MAbs) developed thus far against human carcinomas have led to a more systemic study of human breast tumors. The reactive antigens include a wide variety of cellular products such as receptors, oncogene products, and tumor-associated antigens (TAAs) which can be utilized to “fingerprint” cell populations. The utilization of antibodies as immunologic probes to detect and phenotype cell populations in tissue preparations have moved rapidly from the research area to the clinical application. The MAbs are also increasingly being utilized in serum assays to detect circulating TAAs in patients with breast carcinoma.
KeywordsBreast Carcinoma Benign Breast Disease Intraductal Papilloma High Molecular Weight Glycoprotein Recurrent Breast Carcinoma
Unable to display preview. Download preview PDF.
- 7.R. Tobias, C. Rothwell, J. Wagner, A. Green, and Y. S. Liu, Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D-8/DF3. J. Am. Assoc. Clin. Chem. 31:986 (1985).Google Scholar
- 8.A. van Dalen, J. M. G. Bonfrer, H. Dupree, K. H. Heering, D. L. van der Linde, and W. J. Nooijen, CA15–3 as a marker in the follow-up of patients with breast cancer, in: “Tumor marker” G. Wust, ed. , Steinkopff Verlag, Darmstadt, Germany, pp. 182 (1987).Google Scholar
- 15.A. Thar, F. Gorstein, N. Ohuchi, C. A. Szpak, W. W. Johnson, and J. Schlom, Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72. 3. J. Natl. Cancer Inst. 76:995 (1986).Google Scholar
- 18.R. Muraro, M. Kuroki, D. Wunderlich, D. J. Poole, D. Colcher, A. Thor, J. W. Greiner, J. Simpson, A. Molinoto, P. Noguchi, and J. Scholom, Generation and characterization of B72. 3 second generation monoclonal antibodies reactive with the tumorassociated glycoprotein 72 antigen. Cancer Res. 48:4588 (1988).PubMedGoogle Scholar
- 21.N. Ohuchi, S. Mori, E. Gero, D. Colcher, F. Mochizuki, T. Nishihira, K. Hirayama, N. Matoba, P. M. Kaplan, and J. Schlom, Serum levels of tumor-associated glycoprotein (TAG-72) in patients with carcinoma detected by CA72–4 radioimmunometric assay. (submitted for publication)Google Scholar
- 22.N. Ohuchi, Y. Taira, K. Takahashi, S. Sato, H. Matoba, M. Akimoto, and S. Mori, Comparison of serum levels of CA15–3 and cytoplasmic reactivity of monoclonal antibody DF3 in patients with breast cancer. (submitted for publication).Google Scholar
- 28.N. Ohuchi, D. Wunderlich, J. Fujita, D. Colcher, R. Muraro, M. Nose, and J. Schlom, Differential expression of carcinoembryonic antigen in early gastric adenocarcinomas versus benign gastric lesions defined by monoclonal antibodies reactive with restricted antigen epitopes. Cancer Res. 47:3565 (1987).PubMedGoogle Scholar
- 29.P. Horan Hand, D. Colcher, D. Salomon, J. Ridge, P. Noguchi, and J. Schlom, Influence of spatial configulation of carcinoma cell populations in the expression of a tumor-associated glycoprotein. Cancer Res. 45. 833 (1985).Google Scholar